Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167137 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
A Phase 1 study, sponsored by Synlogic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04167137 is a Phase 1 study that was terminated before completion, run by Synlogic. The registered enrollment target is 32 participants.
The verdict
NCT04167137, a Phase 1 study, was terminated before completion, sponsored by Synlogic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid tumors or lymphoma. The primary objective was to evaluate the safety and tolerability of study treatment, with a secondary objective of assessing preliminary tumor response to treatment and exploratory objectives of evaluating the pharmacokinetics/pharmacodynamics (PK/PD) of study treatment.
Interventions
- DRUG Atezolizumab
- DRUG SYNB1891
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2021-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167137
The ClinicalTrials.gov registry entry for NCT04167137 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04167137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167137 about?
NCT04167137 is a clinical study titled "Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants". This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid tumors or lymphoma. The primary objective was to evaluate the safety and tol...
What is the current status of trial NCT04167137?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-12-12. Estimated completion is 2021-12-09.
What interventions are being tested in trial NCT04167137?
The interventions under investigation include: Atezolizumab (DRUG), SYNB1891 (DRUG).
Who is sponsoring clinical trial NCT04167137?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.